

* * * * *
FILE 'USPAT' ENTERED AT 15:59:49 ON 16 SEP 1999

* * * * *
* U. S. P A T E N T T E X T F I L E *
*
* THE WEEKLY PATENT TEXT AND IMAGE DATA IS CURRENT *
* THROUGH September 14, 1999. *
*
*
* * * * *

=> s paracetamol

L1 399 PARACETAMOL

=> s l1 and stabi?

488743 STABI?
L2 152 L1 AND STABI?

=> s l2 and nitrogen bubbling

290810 NITROGEN
18037 BUBBLING
418 NITROGEN BUBBLING
(NITROGEN(W) BUBBLING)
L3 0 L2 AND NITROGEN BUBBLING

=> s l2 and deoxygenat?

3747 DEOXYGENAT?
L4 1 L2 AND DEOXYGENAT?

=> d

1. 4,840,936, Jun. 20, 1989, Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid; Davide Della Bella, et al., 514/18, 19, 365; 530/331; 548/200, 201 [IMAGE AVAILABLE]

=> d l4 hit

US PAT NO: 4,840,936 [IMAGE AVAILABLE]

L4: 1 of 1

SUMMARY:

BSUM(79)

Such pharmaceutical forms are prepared according to conventional techniques and contain a compound of this invention together with solid or liquid pharmaceutical excipients and additives such as, **stabilizers**, salts for regulating the osmotic pressure, buffers, sweetening and colouring agents suitable for pharmaceutical use.

DETDESC:

DETD(3)

To a suspension of (R)-cysteine hydrochloride (7.88 g; 0.05 moles) and potassium acetate (4.9 g; 0.05 moles) in a mixture of water and ethanol (150 ml; 1:1 v/v) previously **deoxygenated** by a stream of nitrogen, a solution of (2RS)-2-(4-isobutylphenyl)-propanal (10 g; 0.052 moles) in ethanol (10 ml) is added dropwise while stirring at room temperature.

DETDESC:

DETD(8)

To a solution of (R)-cysteine methyl ester hydrochloride (8.12 g; 47.3 mmoles) and potassium acetate (5 g; 51 mmoles) in a mixture of water (45 ml) and methanol (35 ml) previously **deoxygenated** by a stream of nitrogen, a solution of (2RS)-2-(4-isobutylphenyl)-propanal (9 g; 0.0473 moles) in ethanol (10 ml) is added dropwise under stirring at room temperature.

DETDESC:

DETD(69)

To a solution of R-cysteine methyl ester hydrochloride (3.3 g; 0.048 moles) in pyridine (100 ml), **deoxygenated** by a stream of nitrogen and kept under stirring at room temperature, 2-[(3-trifluoromethyl)-phenylamino]-benzaldehyde (11.7 g; 0.0044 moles) is added.

DETDESC:

DETD(200)

The preventing action of the Compounds of this invention on GSH depletion in vivo has been tested in the mouse, more specifically in swiss albino CD/1 females weighting 20 to 30 g. These mice were kept on an empty stomach for 16 hours before treatment. Toxicity was induced by administering 800 mg/kg of **paracetamol** (NAPA) via peritoneal route; this dosage induces a lethal effect in about 70% of the mice. Compounds under test were administered by mouth (2% Suspension in gumarabic) 60 minutes before NAPA.

=> d his

(FILE 'USPAT' ENTERED AT 15:59:49 ON 16 SEP 1999)

L1 399 S PARACETAMOL
L2 152 S L1 AND STABI?
L3 0 S L2 AND NITROGEN BUBBLING
L4 1 S L2 AND DEOXYGENAT?

=> s l1 and deoxygenat?

3747 DEOXYGENAT?
L5 1 L1 AND DEOXYGENAT?

=> d

1. 4,840,936, Jun. 20, 1989, Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid; Davide Della Bella, et al., 514/18, 19, 365; 530/331; 548/200, 201 [IMAGE AVAILABLE]

=> d 15 hit

US PAT NO: 4,840,936 [IMAGE AVAILABLE]

L5: 1 of 1

DETDESC:

DETD(3)

To a suspension of (R)-cysteine hydrochloride (7.88 g; 0.05 moles) and potassium acetate (4.9 g; 0.05 moles) in a mixture of water and ethanol (150 ml; 1:1 v/v) previously **deoxygenated** by a stream of nitrogen, a solution of (2RS)-2-(4-isobutylphenyl)-propanal (10 g; 0.052 moles) in ethanol (10 ml) is added dropwise while stirring at room temperature.

DETDESC:

DETD(8)

To a solution of (R)-cysteine methyl ester hydrochloride (8.12 g; 47.3 mmols) and potassium acetate (5 g; 51 mmols) in a mixture of water (45 ml) and methanol (35 ml) previously **deoxygenated** by a stream of nitrogen, a solution of (2RS)-2-(4-isobutyl-phenyl)-propanal (9 g; 0.0473 moles) in ethanol (10 ml) is added dropwise under stirring at room temperature.

DETDESC:

DETD(69)

To a solution of R-cysteine methyl ester hydrochloride (3.3 g; 0.048 moles) in pyridine (100 ml), **deoxygenated** by a stream of nitrogen and kept under stirring at room temperature, 2-[(3-trifluoromethyl)-phenylamino]-benzaldehyde (11.7 g; 0.0044 moles) is added.

DETDESC:

DETD(200)

The preventing action of the Compounds of this invention on GSH depletion in vivo has been tested in the mouse, more specifically in swiss albino CD/1 females weighting 20 to 30 g. These mice were kept on an empty stomach for 16 hours before treatment. Toxicity was induced by administering 800 mg/kg of **paracetamol** (NAPA) via peritoneal route; this dosage induces a lethal effect in about 70% of the mice. Compounds under test were administered by mouth (2% Suspension in gumarabic) 60 minutes before NAPA.

=> d his

(FILE 'USPAT' ENTERED AT 15:59:49 ON 16 SEP 1999)

L1	399 S PARACETAMOL
L2	152 S L1 AND STABI?
L3	0 S L2 AND NITROGEN BUBBLING
L4	1 S L2 AND DEOXYGENAT?
L5	1 S L1 AND DEOXYGENAT?

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:05:06 ON 16 SEP 1999

=> index caplus, biosis, lifesci, medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

INDEX 'CAPLUS, BIOSIS, LIFESCI, MEDLINE' ENTERED AT 16:05:46 ON 16 SEP 1999

4 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s paracetamol (1) stabilization (1) deoxygenated (1) free radical
scavenger

0 FILES HAVE ONE OR MORE ANSWERS, 4 FILES SEARCHED IN STNINDEX

L1 QUE PARACETAMOL (L) STABILIZATION (L) DEOXYGENATED (L) FREE RADICAL
SCAVEN
GER

=> s paracetamol (1) stabilization

4 FILE CAPLUS
1 FILE BIOSIS
2 FILE MEDLINE

3 FILES HAVE ONE OR MORE ANSWERS, 4 FILES SEARCHED IN STNINDEX

L2 QUE PARACETAMOL (L) STABILIZATION

=> file hits

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.80	1.95

FILE 'CAPLUS' ENTERED AT 16:08:13 ON 16 SEP 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1999 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:08:13 ON 16 SEP 1999

FILE 'BIOSIS' ENTERED AT 16:08:13 ON 16 SEP 1999
COPYRIGHT (C) 1999 BIOSIS(R)

=> set postings off; set interpret off

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=> s 12

L3 7 L2

=> duplicate remove 13

DUPLICATE PREFERENCE IS 'CAPLUS, MEDLINE, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L3

L4 5 DUPLICATE REMOVE L3 (2 DUPLICATES REMOVED)

=> d 14 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 1999 ACS

AN 1996:214244 CAPLUS

DN 124:298660

TI Stabilization of suspensions using sucrose esters and low substituted
n-octenylsuccinate starch-xanthan gum associations.

AU Ntawukulilyayo, J. D.; De Smedt, S. C.; Demeester, J.; Remon, J. P.

CS Laboratory of Pharmaceutical Technology, University of Gent,
Harelbekestraat 72, 9000, Ghent, Belg.

SO Int. J. Pharm. (1996), 128(1,2), 73-9

CODEN: IJPHDE; ISSN: 0378-5173

DT Journal

LA English

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 1999 ACS

AN 1992:433551 CAPLUS

DN 117:33551

TI Stabilization by ethylenediaminetetraacetic acid of amide and other
groups

in drug compounds

AU Fogg, A. G.; Summan, A. M.

CS Chem. Dep., Loughborough Univ. Technol., Loughborough/Leics., LE11 3TU,
UK

SO J. Clin. Pharm. Ther. (1992), 17(2), 107-9

CODEN: JCPTED; ISSN: 0269-4727

DT Journal

LA English

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 1999 ACS

DUPLICATE 1

AN 1989:433303 CAPLUS

DN 111:33303

TI On the mechanism of the pharmacological activity of the new nonsteroidal
antiinflammatory agent 4'-acetamidophenyl-2-(5'-p-toluy-
l-methylpyrrole)acetate

AU Ucelay, M.; Lasheras, B.; Cenarruzabeitia, E.

CS Dep. Pharmacol., Univ. Navarra, Pamplona, Spain

SO Arzneim.-Forsch. (1989), 39(5), 586-9

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA English

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 1999 ACS

AN 1985:528899 CAPLUS

DN 103:128899

TI Effect of crosslinked PVP on the properties of tableting mixtures and
resultant tablets

AU Hermann, A. M. Guyot; Guyot, J. C.

CS Lab. Pharm. Galenique Biopharm., Fac. Pharm., Lille, 59045, Fr.

SO Expo. - Congr. Int. Technol. Pharm., 3rd (1983), Volume 4, 44-54

Publisher: Assoc. Pharm. Galenique Ind., Chatenay-Malabry, Fr.
CODEN: 53YCA8

DT Conference
LA French

L4 ANSWER 5 OF 5 MEDLINE

AN 76266898 MEDLINE

DN 76266898

TI Analgesic nephropathy.

AU Nanra R S

SO MEDICAL JOURNAL OF AUSTRALIA, (1976 May 15) 1 (20) 745-8.
Journal code: M26. ISSN: 0025-729X.

CY Australia

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 197612

DERWENT CLASS: B05 B07
INVENTOR(S): HAAG, T E; SALPEKAR, A
PATENT ASSIGNEE(S): (MLCW) MALLINCKRODT INC
COUNTRY COUNT: 12
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
EP 159852	A	851030	(8544)*	EN	15		<--
R: AT BE CH DE FR GB IT LI LU NL SE							
CA 1261260	A	890926	(8945)				

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 159852	A	EP 85-302470	850409

PRIORITY APPLN. INFO: US 84-600809 840416
REFERENCE PATENTS: 1.Jnl.Ref ; A3...8720 ; GB 818251; No-SR.Pub
INT. PATENT CLASSIF.: A61K009-20
BASIC ABSTRACT:

EP 159852 A UPAB: 930925
A stable, directly tabletable compsn. of two or more pharmaceutically active ingredients which are interactive with each other is produced by blending one of the active ingredients with a binder and a filler, wet granulating the mixture produced in the presence of a solvent, drying then sizing the granulated mixture, and blending the mixture with one or more other active ingredients.
Active ingredients include codeine and its salts which react with non-steroidal analgesics such as acetaminophen, aspirin, ibuprofen and sodium naproxen in such a way as to cause discolouration of the product and to adversely affect the stability of the active ingredients. These cpds. may be used in the present compsns. without these deleterious effects. The codeine may be replaced by oxycodone, hydrocodene and other narcotic and non-narcotic analgesic agents.
ADVANTAGE - The process eliminates the need for wet granulation when two or more interactive cpds. are present.
0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB
MANUAL CODES: CPI: B04-A04; B10-C03; B10-C04B; B10-C04C; B10-D03; B12-C05; B12-D01; B12-M11

=> s fr 274923/pn

L2 0 FR 274923/PN
(FR274923/PN)

=> s fr 2747923/pn

L3 1 FR 2747923/PN
(FR2747923/PN)

=> d iall

L3 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 98-002241 [01] WPIDS
DOC. NO. CPI: C98-000820
TITLE: Use of antipyretic and benzodiazepine derivative stabilised by benzoic acid, salt or derivative - to treat
e.g. infant convulsions, arthrosis and other painful

disorders..
DERWENT CLASS: A96 B02 B05
INVENTOR(S): BESSE, J
PATENT ASSIGNEE(S): (CRIN-N) LAB CRINEX SA
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
FR 2747923	A1	971031	(9801)*		14	A61K047-12	<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
FR 2747923	A1	FR 96-5259	960425

PRIORITY APPLN. INFO: FR 96-5259 960425
INT. PATENT CLASSIF.:

MAIN: A61K047-12
INDEX: A61K031:165, A61K031:55, A61K047-12; A61K031:22,
A61K031:55, A61K047-

BASIC ABSTRACT:

FR 2747923 A UPAB: 980107

Composition (I) comprises at least one benzodiazepine compound and an antipyretic and is stabilised by benzoic acid, a salt and/or a derivative.

USE - (I) is used where a benzodiazepine combined with an antipyretic

is required e.g. in the treatment of arthrosis and other painful pathologies. (I) is particularly used to treat convulsions in unweaned babies. (I) are preferably administered orally as aqueous solutions.

ADVANTAGE - The compositions have a practical shelf life due to the benzoic acid stabiliser and no longer have to be formulated immediately prior to use.

Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: A12-V01; B06-D07; B10-C04C; B14-C04; B14-J07;
B14-N01

=> s ep 715857/pn

L4 1 EP 715857/PN
(EP715857/PN)

=> d iall

L4 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 96-269763 [28] WPIDS
DOC. NO. CPI: C96-085750
TITLE: Oral preps. esp. tablets of analgesics and
antirheumatics - contg. disintegrant and disintegration
accelerator esp. aminoacid.
DERWENT CLASS: A96 B05
INVENTOR(S): DURR, M; GAJDOS, B; DUERR, M
PATENT ASSIGNEE(S): (RHON) RHONE-POULENC RORER GMBH; (RHON) RHONE-POULENC
RORER GMBH
COUNTRY COUNT: 22
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
EP 715857	A2	960612	(9628)*	GE	13	A61K047-18	<--

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 DE 4444051 A1 960613 (9629) 10 A61K031-60
 AU 9537945 A 960620 (9632) A61K009-02
 ZA 9510427 A 960828 (9639) 41 A61K000-00
 CA 2164777 A 960611 (9640) A61K047-22
 JP 08208520 A 960813 (9642) 9 A61K047-16
 EP 715857 A3 970528 (9732) A61K047-18 <--
 MX 9505065 A1 970101 (9816) A61K031-195
 AU 697187 B 981001 (9851) A61K009-02

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 715857	A2	EP 95-118095	951117
DE 4444051	A1	DE 94-4444051	941210
AU 9537945	A	AU 95-37945	951120
ZA 9510427	A	ZA 95-10427	951208
CA 2164777	A	CA 95-2164777	951208
JP 08208520	A	JP 95-312613	951130
EP 715857	A3	EP 95-118095	951117
MX 9505065	A1	MX 95-5065	951205
AU 697187	B	AU 95-37945	951120

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 697187	B Previous Publ.	AU 9537945

PRIORITY APPLN. INFO: DE 94-4444051 941210

REFERENCE PATENTS: No-SR.Pub ; 5.Jnl.Ref ; EP 284039; EP 468929; EP 478838;
 EP 636365; EP 715846; GB 749285; JP 60013712; JP
 62045523; JP 62081316; JP 62205025; US 3845210; US
 4716153; US 4866046

INT. PATENT CLASSIF.:

MAIN: A61K000-00; A61K009-02; A61K031-195; A61K031-60;
 A61K047-16; A61K047-18; A61K047-22
 SECONDARY: A61K009-20; A61K009-22; A61K031-215

BASIC ABSTRACT:

EP 715857 A UPAB: 960719

An oral preparation comprises a solid compsn. contg. at least one active agent (I), at least one disintegrant, pharmaceutical adjuvants, and a component (II) that accelerates the disintegration of the compsn. in the mouth or in liquids. (II) is a water-soluble cpd. that is an amino acid, its salt and/or its deriv.

Pref. the disintegrant is starch, cellulose, alginic acid, casein, and/or derivs. of these and/or insol. polyvinyl pyrrolidone. (II) is glycine, proline, hydroxyproline, lysine and/or their salts and/or derivs.

Pref. the prepn. contains a hydrophilic (I) embedded in or coated with hydrophobic material. The hydrophobic material is a matrix or coating of shellac, stearic acid, gelatin, zein, gum arabic, cellulose deriv., acrylic acid polymer and/or vinyl acetate polymer.

USE - The prepn. contains an analgesic and/or antirheumatic agent, such as paracetamol, acetyl salicylic acid, ketoprofen, ibuprofen and/or diclofenac sodium (claimed). It is used to treat all sorts of painful conditions, including headache, rheumatism, pain in the limbs, migraine, toothache, gout, swelling, and inflammation. The prepn. is in the form of tablets or a granulate.

ADVANTAGE - The tablets disintegrate readily without requiring long chewing, but are strong enough not to be damaged during mfr. or transport.

Dwg.0/0

FILE SEGMENT: CPI
 FIELD AVAILABILITY: AB; DCN

MANUAL CODES:

CPI: A12-V01; B04-C02A; B04-C02B; B04-C02D; B04-N02;
B05-A01B; B07-D03; B10-B02; B10-C03; B10-C04C;
B10-D03; B12-M11B; B14-C01; B14-C06

=> s de 3306012/pn

L5 1 DE 3306012/PN
(DE3306012/PN)

=> d iall

L5 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 84-214177 [35] WPIDS
DOC. NO. CPI: C84-089991
TITLE: Paracetamol granules prodn. - by granulation with binder
in fluidised bed at low temp..
DERWENT CLASS: B05
INVENTOR(S): NOLTNER, G
PATENT ASSIGNEE(S): (FARH) HOECHST AG
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
DE 3306012	A	840823	(8435)*		15	<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 3306012	A	DE 83-3306012	830222

PRIORITY APPLN. INFO: DE 83-3306012 830222

INT. PATENT CLASSIF.: A61K031-16

BASIC ABSTRACT:

DE 3306012 A UPAB: 930925

Free-flowing paracetamol granules are produced by withdrawing moist paracetamol (I) from a centrifuge, converting it into a suspension contg. microfine (I) and either 2-20% starch or 1-5% hydroxypropyl methyl cellulose (HPMC) as the sole binder, and spraying the suspension into an air-fluidised bed of (I)/starch or (I)/HPMC granules. The temp. of the fluidised bed is from 40 to (for short periods) 80 deg. C and the relative

humidity of the outlet air is not more than 40% (measured at 50 deg. C).

USE - (I) is an analgesic and antipyretic agent. The process employs lower temps. than spray drying processes, thus avoiding discoloration due to thermal decompn. of (I), and is simpler than the fluidised-bed process

of DE 3150557.

0/1

FILE SEGMENT: CPI

FIELD AVAILABILITY: AB

MANUAL CODES: CPI: B10-D03; B12-D01; B12-D08; B12-M11

=> s ep 356325/pn

L6 1 EP 356325/PN
(EP356325/PN)

=> d iall

L6 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 90-060999 [09] WPIDS

DOC. NO. CPI: C90-026523
TITLE: Pharmaceutical compsns. contg. water-insol. drugs -
together with glyceride gelled with cellulosic polymer.
DERWENT CLASS: A96 B05 B07
INVENTOR(S): AIACHE, J
PATENT ASSIGNEE(S): (AIAC-I) AIACHE J; (AIAC-I) AIACHE J M; (VEPR-N) VEPROL
COUNTRY COUNT: 13
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
EP 356325	A	900228	(9009)*	FR	15		<--
R: AT BE CH DE ES GB GR IT LI LU NL SE							
FR 2635463	A	900223	(9015)				
EP 356325	B1	940504	(9418)	FR	15	A61K047-00	<--
R: AT BE CH DE GB IT LI LU NL SE							
DE 68915079	E	940609	(9424)			A61K047-00	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 356325	A	EP 89-402306	890818
FR 2635463	A	FR 88-11037	880819
EP 356325	B1	EP 89-402306	890818
DE 68915079	E	DE 89-615079	890818
		EP 89-402306	890818

FILING DETAILS:

PATENT NO	KIND	PATENT NO
DE 68915079	E Based on	EP 356325

PRIORITY APPLN. INFO: FR 88-11037 880819
REFERENCE PATENTS: 3.Jnl.Ref ; 2.Jnl.Ref
INT. PATENT CLASSIF.: A61K009-10; A61K031-65; A61K047-00
SECONDARY: A61K009-10; A61K031-65

BASIC ABSTRACT:

EP 356325 A UPAB: 940705
Pharmaceutical compsns. for oral, topical or parenteral admin. to humans or animals contain up to 25 wt.% of a sparingly water-soluble drug (I) together with a glyceride (II) gelled with a cellulosic polymer (III).
(I) is pref. doxycycline hyclate (hydrochloride solvated with EtOH and H2O), paracetamol, pyrantel pamoate, amoxycillin or a vitamin mixt.
(II) is 'gabrafil' (RTM), 'Migliol' (RTM), 'abrafac' (RTM),
'Transcutol' (RTM) and/or a natural oil. (III) is ethyl cellulose or carboxymethyl cellulose and is present in an amt. of 1-10 wt.%.

ADVANTAGE - The compsns. have good storage stability, even at high concns. of (I), can be administered by various routes (including i.m. or s.c. injection) without causing local irritation, and provide substaisted release of (I), e.g. over 40-84 hrs. on oral admin.

0/0

Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: A03-A04A1; A12-S; A12-V01; B02-D; B02-P02; B02-T;
B03-L; B04-B01C; B04-C02A2; B07-B01; B07-D12;
B10-D03; B10-E04C; B10-G02; B12-M10A

=> s ca 2084028/pn

L7 1 CA 2084028/PN
(CA2084028/PN)

=> d iall

L7 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 93-259193 [33] WPIDS
DOC. NO. CPI: C93-115104
TITLE: Compsn. for dissolution in hot water for treating colds
and influenza - contains an analgesic, an antihistamine,
an antitussive, a decongestant, citric acid, bi
carbonate
and calcium carbonate.
DERWENT CLASS: B05
INVENTOR(S): PANDYA, H B
PATENT ASSIGNEE(S): (MILE) MILES INC
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC	
CA 2084028	A	930528	(9333)*		12	A61K031-16	<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CA 2084028	A	CA 92-2084028	921127

PRIORITY APPLN. INFO: US 91-799033 911127
INT. PATENT CLASSIF.:

MAIN: A61K031-16
SECONDARY: A61K031-19; A61K031-60
BASIC ABSTRACT:

CA 2084028 A UPAB: 931119
A compsn. for dissolution in hot water, for treating cold and flu
symptoms
comprises, as wt. %: a) 0.9-17% analgesic selected from acetaminophen,
acetylsalicylic acid, ketoprofen and ibuprofen; b) 0.07-0.14%
antihistamine; c) 0.4-1.2% antitussive; d) 1-2% decongestant; e) 10-20%
citric acid; f) 1.5-2.2% Na or KHCO₃; g) 1.5-3% CaCO₃; h) 2-4% flavours
and sweeteners; i) 1.5-2.5% tablet lubricants; and j) further tableting
aids.

The antihistamine is e.g. chlorpheniramine maleate, brompheniramine
maleate or pyrilamine maleate. The antitussive is e.g. dextromethorphan
hydrobromide, and the decongestant is phenylpropanolamine tartrate or
bitartrate, phenylephrine bitartrate or pseudoephedrine sulphate or the
corresp. HCl salts. Tableting aids include inert fillers or binders,
partic. mannitol. Polyvinyl pyrrolidone, organopolysiloxane or dioctyl
sodium sulphosuccinate surfactants may be included.

USE/ADVANTAGE - The new compsn. is an effervescent tablet for
dissolution in hot water, without the conventional use of sugar and
without glycine. The bitter taste of e.g. acetaminophen is masked by
CaCO₃.

Dwg. 0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: B04-A04; B05-A04; B07-D04C; B10-B03B; B10-C02;
B10-C03; B10-C04B; B10-C04C; B10-D03; B12-D06;
B12-K01; B12-K06; B12-M11B